New Alzheimer’s Prevention Trial Part of US National Plan

May 18, 2012 — An ambitious National Alzheimer’s Plan announced this week by the Department of Health and Human Services to address the growing threat of Alzheimer’s disease (AD) in the United States includes funding for the first prevention trial in people genetically predisposed to develop early symptoms.

The double-blind, placebo-controlled study will test the drug crenezumab, an antibody that targets beta-amyloid, in a large extended family in Colombia, many of whom carry genetic risk mutations. Typically, cognitive impairment begins at around age 45 in affected individuals. [Read more…]